U.S set to approve second COVID-19 vaccine




This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic. (Photo by JOEL SAGET / AFP) / “The erroneous mention[s] appearing in the metadata of this photo by JOEL SAGET has been modified in AFP systems in the following manner: [This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic.] instead of [This illustration picture taken in a studio in Paris on November 16, 2020, shows a syringe and a vial with the logo of US biotech firm Moderna.]. Please immediately remove the erroneous mention[s] from all your online services and delete it (them) from your servers. If you have been authorized by AFP to distribute it (them) to third parties, please ensure that the same actions are carried out by them. Failure to promptly comply with these instructions will entail liability on your part for any continued or post notification usage. Therefore we thank you very much for all your attention and prompt action. We are sorry for the inconvenience this notification may cause and remain at your disposal for any further information you may require.”

Abuja (Sundiata Post) – The government is set to approve a second vaccine after it was endorsed by a panel of health experts.

The head of the Food and Drug Administration (FDA) has announced that his agency would move quickly to authorise the new Moderna vaccine, allowing the company to begin shipping millions of doses.

It comes days after the US began its largest ever immunisation campaign with the rollout of the Pfizer/BioNTech vaccine.

The US has recorded more Covid-19 cases and deaths than any other country as the has now passed 300,000.

The covid-19 advisory panel on Thursday, December 17,  voted 20-0 with one abstention that the benefits of the Moderna vaccine outweigh the risks for those aged 18 and over. The same committee last week backed the Pfizer/BioNTech vaccine, leading to its authorisation for emergency use the following day.

Following the panel’s endorsement, FDA commissioner Stephen Hahn said his agency had informed Moderna that it would work “rapidly” towards issuing emergency use authorisation.
The agency says the Moderna vaccine is safe and 94% effective.
The US has agreed to purchase 200 million doses, and six million could be ready to ship as soon as the vaccine gets FDA approval.

“To go from having a sequence of a virus in January to having two available in December is a remarkable achievement,” said Dr James Hildreth, a member of the expert panel and CEO of Meharry Medical College in Tennessee.

The Moderna vaccine requires temperatures of around -20C for shipping – similar to a normal freezer unlike the Pfizer vaccine which requires temperatures closer to -75C, making transport logistics much more difficult.
Like the Pfizer jab, the Moderna vaccine also requires a second booster shot which  comes 28 days after the first.

Whatapp News

Telegram News